Re­genxbio said it no longer ex­pects to file for FDA ap­proval of its Hunter syn­drome gene ther­a­py in the near fu­ture af­ter the pro­gram was...

As­traZeneca, Io­n­is, Cy­to­ki­net­ics, No­var­tis and CRISPR Ther­a­peu­tics, among oth­ers, will get a sense of the mar­ket po­ten­tial of their heart drugs when da­ta is pre­sent­ed...

Twin­Strand Bio­sciences wins patent case: The DNA se­quenc­ing com­pa­ny, which spun out of the Uni­ver­si­ty of Wash­ing­ton, an­nouncedon Mon­day that it won a patent...

Two re­cent deals are fo­cus­ing at­ten­tion on a rel­a­tive­ly rare struc­ture for biotech buy­outs: the op­tion-to-ac­quire.

Drug de­vel­op­ers are on pace to have one of...

Roche is spend­ing $190 mil­lion up­front to li­cense a non-in­cretin obe­si­ty drug from South Ko­rea’s Han­mi Pharm.

The deal rep­re­sents the lat­est in a string...

The bio­phar­ma in­dus­try tipped the scales on can­cer re­search years ago. Where the fed­er­al gov­ern­ment once played a ma­jor role in de­ter­min­ing what was stud­ied...